Results 71 to 80 of about 6,032 (153)

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

open access: yesArquivos Brasileiros de Cardiologia
Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI).
Igor Matos Lago   +9 more
doaj   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 470-479, August 2025.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer   +14 more
wiley   +1 more source

The role of intravenous tirofiban in patients undergoing endovascular treatment for acute intracranial atherosclerotic occlusion

open access: yesJournal of Stroke and Cerebrovascular Diseases
BACKGROUND AND PURPOSE: Previous reports regarding the impact of tirofiban on patients undergoing endovascular treatment for acute ischemic stroke have shown inconsistencies.
Zhiping Bu, MD   +7 more
doaj   +1 more source

The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume

open access: yesScientific Reports
This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on
Kwang-Chun Cho   +4 more
doaj   +1 more source

Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives.

open access: yesPLoS ONE
BackgroundThe RESCUE BT2 trial recently showcased the efficacy of tirofiban in treating acute ischemic stroke (AIS) without large or medium-sized vessel occlusion.
Li Wang   +12 more
doaj   +1 more source

Desenlaces clínicos en una cohorte de pacientes con síndrome coronario agudo y administración intracoronaria de tirofiban

open access: yesRevista Colombiana de Cardiología, 2015
Introducción: Los inhibidores de glicoproteína IIb/IIIa reducen los eventos cardiovasculares mayores adversos (MACE) en pacientes con síndrome coronario agudo.
Julián Ochoa   +5 more
doaj   +1 more source

Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome

open access: yesSão Paulo Medical Journal
CONTEXT AND OBJECTIVES: Glycoprotein inhibitors (abciximab, eptifibatide and tirofiban) are used in patients with unstable angina and non-ST-segment elevation myocardial infarction before percutaneous coronary intervention.
Antonio de Padua Mansur   +5 more
doaj   +1 more source

Effect of Intravenous Tirofiban Versus Placebo on First‐Pass Successful Reperfusion in Endovascular Stroke Thrombectomy: Insights From the RESCUE BT Randomized Clinical Trial

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background First‐pass successful reperfusion (FPSR), defined as a successful/complete reperfusion achieved after a single thrombectomy pass, is predictive of favorable outcome in patients with acute ischemic stroke with large‐vessel occlusion.
Junjie Yuan   +27 more
doaj   +1 more source

Home - About - Disclaimer - Privacy